For the past over 20 years, the R&D team of Peg-Bio has been focusing on the development of recombinant biological drugs, mainly long-acting therapeutic enzymes and peptide drugs. During this period, Peg-Bio has developed 4 core technology platforms with proprietary intellectual property, and over 10 biological drugs have been developed and reached clinical stage or already approved. Furthermore, several more innovative biological drugs (either FIC or BIC) are under research. Based on our successful track record of developing biological drugs, Peg-Bio also provides high quality CRDMO services to over ten well-known biopharmaceutical companies. Our CRDMO unit is a multidisciplinary team covering protein model analysis, production and registration service for drug products – together they provide one-stop service for customers from drug discovery, CMC, IND to NDA. IMED Bioscience, a wholly owned subsidiary of Peg-Bio, focuses on the R&D, production and global marketing & sales of Recombinant Proteases. IMED has a GMP production line of proteases with fermentation scale up to 3,000L. IMED's main products include rLys-C, rKex2, rTP, rCPB and rEK, etc.